In this real-world analysis of T2DM patients, our findings suggest that SGLT2 inhibitors are associated with lower risk of heart failure hospitalization than DPP4 inhibitors, specifically among patients older than 65 years of age or those with a prior history of diabetic complications. The gene discussed is DPP4; the disease is heart failure.